198 related articles for article (PubMed ID: 18767043)
1. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Int J Cancer; 2008 Dec; 123(11):2636-43. PubMed ID: 18767043
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
3. Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis.
Veltri RW; Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW
Prostate; 2008 Dec; 68(16):1806-15. PubMed ID: 18767028
[TBL] [Abstract][Full Text] [Related]
4. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
5. Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy.
Veltri RW; Isharwal S; Miller MC; Epstein JI; Partin AW
Prostate; 2010 Sep; 70(12):1333-9. PubMed ID: 20623633
[TBL] [Abstract][Full Text] [Related]
6. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
[TBL] [Abstract][Full Text] [Related]
7. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
8. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
9. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.
Ross JS; Nazeer T; Church K; Amato C; Figge H; Rifkin MD; Fisher HA
Cancer; 1993 Nov; 72(10):3020-8. PubMed ID: 8106140
[TBL] [Abstract][Full Text] [Related]
10. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
Ricciardelli C; Jackson MW; Choong CS; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2008 Jun; 68(8):830-8. PubMed ID: 18324648
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
17. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
Bill-Axelson A; Holmberg L; Garmo H; Taari K; Busch C; Nordling S; Häggman M; Andersson SO; Andrén O; Steineck G; Adami HO; Johansson JE
N Engl J Med; 2018 Dec; 379(24):2319-2329. PubMed ID: 30575473
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population.
Megas G; Chrisofos M; Anastasiou I; Tsitlidou A; Choreftaki T; Deliveliotis C
Asian J Androl; 2015; 17(1):98-105. PubMed ID: 25219910
[TBL] [Abstract][Full Text] [Related]
19. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
